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Epidemiology of acute kidney injury (AKI) is supposedly a
well-characterized topic. Large population studies developed
in the 1990s demonstrated a higher incidence of AKI than
previously suspected. More importantly, this incidence was
higher among critically ill patients while mortality rates
rose dramatically in this setting. In these studies an overall
incidence of around five per cent of AKI was found in ICU
with an accompanyingmortality in over fifty per cent of cases.
Recently we have witnessed a significant change in this
field with the development of a classification system for
staging kidney damage (RIFLE, AKIN, and KDIGO). These
systems have marked a shift from static to a dynamic concept
of AKI based in changes in kidney function regardless of the
net functional capability found in our patients. This change
has had an important impact on the way intensivists look at
the kidney problem (focusing now on early secondary pre-
vention in order to arrest the process), but this has created an
unexpected problem due to a dramatic increase in the num-
ber of patients that we label as AKI. To clarify the real impact
of AKI we must admit that all the figures derived from the
early studies are no longer useful and consequently new epi-
demiological studies have been developed all over the world.
In an interesting review “Epidemiology of acute kidney
injury in the intensive care unit” by J. Case et al. published
in a recent issue of Clinical Care Research and Practice, the
authors highlighted the complexity of this problem that is
yet to be solved. Following J. Case et al., incidence of AKI in
critically ill patients has risen during the past decade due to
increased acuity as well as increased recognition. Following
recent standards, overall incidence ranges from 20% to 50%
but, as this paper emphasizes, current rates are dependent on
the specific ICU population under study, with lower rates for
scheduled surgery and higher rates in septic patients.
A note of interest is that even when measured incidence
of AKI varied from five per cent to fifty per cent, reported
mortality was still around 50% and this makes us question
the real impact of AKI detection.What is required in the near
future is to fully understand AKI, define its incidence among
specific population groups, and evaluate the real impact of
this improved capability of AKI detection.
If we consider the aforementioned impact of new stage
systems and the fact that we lack effective treatment to avoid
or limit kidney damage, we are faced with the prospect of
providing effective preventive measures. To be effective, this
approach requires, primarily, the identification of high-risk
populations, but until now, studies showed different risk
factors dependent on the geographical setting, the population
addressed, and the particular selection of the investigators.
In regards to this problem, an interesting meta-analysis by
Cartin-Ceba et al. “Risk factors for development of Acute
kidney injury in critically ill patients: A systematic review
and meta-analysis of observational studies” analyzed data
extracted from 31 studies comprising 504,535 critically ill
patients from a wide variety of ICUs. This meta-analysis
showed a significantly increased risk of AKI in the following:
older patients, those admitted after surgery, more severely
ill, and patients with higher baseline creatinine or when
nephrotoxic drugs are used.
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Historically the screening and diagnosis of AKI have been
based on a surrogate of glomerular filtration rate, serum
creatinine. This is regarded as the most practical approach
considering that creatinine is affordable and universally
available and has been potentiated with the application of
new staging systems based on changes of serum creatinine as
markers for proportional changes in creatinine clearance. In
this special issue, G. Seller-Pe´rez et al. expose the potential
pitfalls of this approach in a review titled “Estimating kidney
function in the critically ill patients”.
When basal creatinine is not available in the RIFLE stag-
ing system, an estimation extracted from theMDRDequation
is an acceptable alternative. The estimation of creatinine
clearance by different equations is an accepted guide for the
dosage of different drugs in the ICU setting, even when
clinicians are well aware of the fact that these equations were
developed for the use on patients with chronic kidney disease
and have been scarcely validated for acutely ill patients. In
regards to this issue, C. Kirwan et al. presented a study (Esti-
mated glomerular filtration rate correlates poorly with four-
hour creatinine clearance in critically ill patients with acute
kidney injury) aiming to test whether creatinine or cystatin
C based eGFR equations offer an accurate representation of
creatinine clearance in critically ill patients with AKI and not
surprisingly found that these equationswere unreliable in this
setting. The authors concluded (and we definitely agree with
their position) that these equations should not be used to
describe renal function in ICU patients with AKI and that
new standards of validation for these equations are required.
If we consider the importance of early prevention and
the drawbacks of creatinine as diagnostic tool for AKI
(mainly the delay between damage and change of serum
levels) it is easy to understand the recent interest in the
study of new markers of kidney damage (both functional or
structural damage biomarkers). The role of the most promis-
ing biomarkers [neutrophil gelatinase-associated lipocalin
(NGAL), cystatin C (Cys C), kidney injury molecule-1 (KIM-
1), Interleukin-18 (IL-18) and liver-type fatty acids binding
protein (L-FABP)] is explored by Tsigou et al. in the inter-
esting review paper “Role of new biomarkers: functional and
structural damage.” This paper highlights important issues
when evaluating the role of new biomarkers for AKI and
some of these are also seen in the study that A. Royakkers
et al. present in this issue (Systemic and urinary neutrophil
gelatinase-associated lipocalin are poor predictors of acute kid-
ney injury in unselected critically Ill patients). These authors
did not find urinary or plasma NGAl useful as markers for
AKI development in an unselected population, but (as they
point out in their discussion) these results conflict with other
published studies focusing on heterogeneous ICU popula-
tions. Biomarkers for AKI are still in a development stage
and we need further studies in order to define their actual
capability for early detection, possible interferences in their
values, ideal cut-off values in different clinical settings and
whether the simultaneous use of a battery of biomarkers,
could have an impact on kidney injury detection.
New trends must be found not only in AKI definition
or diagnosis but in other areas too. Until recently, aggressive
fluid administration as a mean to ensure an adequate perfu-
sion was the cornerstone of the intensivists’ earlier interven-
tion. This approach was considered the most critical aspect
regarding AKI prevention. After the publication of some
important studies demonstrating that in fact this approach
may not be adequate (and can even be detrimental) we must
now reassess the role of volume resuscitation in the critically
ill patient and define which patients are candidates for an
aggressive fluid resuscitation and which fluid should be used
for each scenario. These questions and much more (evalua-
tion of volume status in critically ill patients, disturbances in
the distribution of body water or its effect on creatinine or
urea kinetics, i.e.) are addressed in the review fromM. Labib
et al. titled “Volume management in the critically ill patient
with acute kidney injury”.
Finally, A. Leung et al. in the original study titled “A ret-
rospective review of the use of regional citrate anticoagulation
in continuous venovenous hemofiltration (CVVH) for critically
ill patients” address another current issue, the best anticoagu-
lation strategy for keeping permeable renal replacement
(RRT) circuits. Recently different investigators presented
interesting results demonstrating that citrate anticoagulation
is efficient and safe even in circumstances that were previ-
ously prohibited. The only important drawback for this
strategy is the requirement of a serum ionic calcium control
and the use for dialysis and reinfusion fluids with a different
composition (devoid of calcium and with a lower concentra-
tion of bicarbonate) from the commercial solutions available.
A. Leung presented a protocol devised for a widely available
RRT monitor that is safe and easy to perform with excellent
results in terms of circuit survival.
The papers on this topic present to the reader a com-
prehensive picture of the acute kidney injury problem in the
ICU setting: dire necessity for early detection beside a lack of
adequate tools for early diagnosis; promising biomarkers that
raise expectation but are still in the developmental stage and
far from being a clinical routine; the fact that almost every
other patient will develop AKI, but we have no effective
measures to prevent or treat it and, underlying all these facts,
knowledge that AKI worsens dramatically the prognosis of
our patients.These facts, together with the problems resulting
from the limited options in the treatment and the increased
resources imposed by its management, make AKI a focus of
growing interest among professionals managing critically ill
patients.
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